|
1.
|
Zavoral M, Minarikova P, Zavada F, Salek C
and Minarik M: Molecular biology of pancreatic cancer. World J
Gastroenterol. 17:2897–2908. 2011. View Article : Google Scholar
|
|
2.
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
4.
|
Sultana A, Tudur Smith C, Cunningham D,
Starling N, Neoptolemos JP and Ghaneh P: Meta-analyses of
chemotherapy for locally advanced and metastatic pancreatic cancer:
results of secondary end points analyses. Br J Cancer. 99:6–13.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Zalatnai A: Pancreatic cancer - a
continuing challenge in oncology. Pathol Oncol Res. 9:252–263.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ahrendt SA and Pitt HA: Surgical
management of pancreatic cancer. Oncology. 16:725–734.
2002.PubMed/NCBI
|
|
7.
|
Wray CJ, Ahmad SA, Matthews JB and Lowy
AM: Surgery for pancreatic cancer: recent controversies and current
practice. Gastroenterol. 128:1626–1641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hilbig A and Oettle H: Gemcitabine in the
treatment of metastatic pancreatic cancer. Expert Rev Anticancer
Ther. 8:511–523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Toschi L, Finocchiaro G, Bartolini S,
Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy.
Future Oncol. 1:7–17. 2005. View Article : Google Scholar
|
|
10.
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD:
Improvements in survival and clinical benefit with as first-line
therapy for patients with advanced pancreas cancer: a randomized
trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
11.
|
Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF,
Liu XJ, Cao GS, Newmark HL, Conney AH and Chang RL: Effect of
intravenous infusions of 12-0-tetradecanoyl-phorbol-13-acetate
(TPA) in patients with myelocytic leukemia: Preliminary studies on
therapeutic efficacy and toxicity. Proc Natl Acad Sci USA.
95:5357–5361. 1998. View Article : Google Scholar
|
|
12.
|
Strair RK, Schaar D, Goodell L, Aisner J,
Chin KV, Eid J, Senzon R, Cui XX, Han ZT, Knox B, Rabson AB, Chang
R and Conney A: Administration of a phorbol ester to patients with
hematological malignancies: preliminary results from a phase I
clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer
Res. 8:2512–2518. 2002.
|
|
13.
|
Schaar D, Goodell L, Aisner J, Cui XX, Han
ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y,
Rubin EH, Conney A and Strair RK: A phase I clinical trial of
12-O-tetradecanoylphorbol-13-acetate for patients with
relapsed/refractory malignancies. Cancer Chemother Pharmacol.
57:789–795. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zheng X, Chang RL, Cui XX, Kelly KA, Shih
WJ, Lin Y, Strair R, Suh J, Han ZT, Rabson A and Conney AH:
Synergistic effects of clinically achievable concentrations
of12-O-tetradecanoylphorbol-13-acetate in combination with
all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium
butyrate on differentiation in HL-60 cells. Oncol Res. 12:419–427.
2000.
|
|
15.
|
Hansson A, Marín YE, Suh J, Rabson AB,
Chen S, Huberman E, Chang RL, Conney AH and Zheng X: Enhancement of
TPA-induced growth inhibition and apoptosis in myeloid leukemia
cells by BAY 11-7082, an NF-κB inhibitor. Int J Oncol. 27:941–948.
2005.PubMed/NCBI
|
|
16.
|
Avila GE, Zheng X, Cui XX, Ryan AD,
Hansson A, Suh J, Rabson AB, Chang RL, Shih WJ, Lin Y, Crowell P,
Lu YP, Lou YR and Conney AH: Inhibitory effects of
12-O-tetradecanoylphorbol-13-acetate alone or in combination with
all-trans retinoic acid on the growth of cultured human pancreas
cancer cells and pancreas tumor xenografts in immunodeficient mice.
J Pharmacol Exp Ther. 315:170–187. 2005. View Article : Google Scholar
|
|
17.
|
Bond JA, Gescher AJ, Verschoyle RD,
Lemoine NR, Errington R, Wiltshire M, Smith PJ and Wynford-Thomas
D: Cytotoxic action of phorbol esters on human pancreatic cancer
cells. Int J Cancer. 121:1445–1454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Salabat MR, Ding XZ, Flesche JB, Ujiki MB,
Robin TP, Talamonti MS, Bell RH Jr and Adrian TE: On the mechanisms
of 12-O-tetradecanoylphorbol-13-acetate-induced growth arrest in
pancreatic cancer cells. Pancreas. 33:148–155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Detjen KM, Brembeck FH, Welzel M, Kaiser
A, Haller H, Wiedenmann B and Rosewicz S: Activation of protein
kinase Calpha inhibits growth of pancreatic cancer cells via
p21(cip)-mediated G(1) arrest. J Cell Sci. 113:3025–3035.
2000.PubMed/NCBI
|
|
20.
|
Ploszaj T, Motyl T, Orzechowski A,
Zimowska W, Wareski P, Skierski J and Zwierzchowski L:
Antiapoptotic action of prolactin is associated with up-regulation
of Bcl-2 and down-regulation of Bax in HC11 mouse mammary
epithelial cells. Apoptosis. 3:295–304. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zheng X, Chang RL, Cui XX, Avila GE, Lee
S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A and
Conney AH: Inhibitory effect of12-O-tetradecanoylphorbol-13-acetate
alone or in combination with all-trans-retinoic acid on the growth
of LNCaP prostate tumors in immunodeficient mice. Cancer Res.
64:1811–1820. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zheng X, Cui XX, Huang MT, Liu Y, Shih WJ,
Lin Y, Lu YP, Wagner GC and Conney AH: Inhibitory effect of
voluntary running wheel exercise on the growth of human pancreatic
Panc-1 and prostate PC-3 xenograft tumors in immunodeficient mice.
Oncol Rep. 19:1583–1588. 2008.PubMed/NCBI
|
|
23.
|
Zhao L, Wientjes MG and Au JL: Evaluation
of combination chemotherapy: integration of nonlinear regression,
curve shift, isobologram, and combination index analyses. Clin
Cancer Res. 10:7994–8004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Hsu JC: Comparisons: Theory and Methods.
Chapman and Hall; New York, NY: 1996, View Article : Google Scholar
|
|
25.
|
Zheng X, Chang RL, Cui XX, Avila GE,
Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN and
Conney AH: Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in
combination with paclitaxel (Taxol) on prostate cancer LNCaP cells
cultured in vitro or grown as xenograft tumors in immunodeficient
mice. Clin Cancer Res. 12:3444–3451. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Van Duuren BL: Tumor-promoting agents in
two-stage carcinogenesis. Prog Exp Tumor Res. 11:31–68.
1969.PubMed/NCBI
|
|
27.
|
Hecker E: Structure-activity relationships
in diterpene esters irritant and cocarcinogenic to mouse skin.
Mechanisms of Tumor Promotion and Cocarcinogenesis. Slaga TJ, Sivak
AJ and Boutwell RK: Raven; New York, NY: pp. 11–49. 1978
|
|
28.
|
Huberman E and Callaham MF: Induction of
terminal differentiation in human promyelocytic leukemia cells by
tumor-promoting agents. Proc Natl Acad Sci USA. 76:1293–1297. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Lotem J and Sachs L: Regulation of normal
differentiation in mouse and human myeloid leukemic cells by
phorbol esters and the mechanism of tumor promotion. Proc Natl Acad
Sci USA. 76:5158–5162. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Rovera G, O’Brien TG and Diamond L:
Induction of differentiation in human promyelocytic leukemia cells
by tumor promoters. Science. 204:868–870. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Cui XX, Chang RL, Zheng X, Woodward D,
Strair R and Conney AH: A sensitive bioassay for measuring blood
levels of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients:
preliminary pharmacokinetic studies. Oncol Res. 13:169–174.
2002.PubMed/NCBI
|
|
32.
|
Voutsadakis IA: Molecular predictors of
gemcitabine response in pancreatic cancer. World J Gastrointest
Oncol. 3:153–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Greenhalf W and Thomas A: Combination
therapy for the treatment of pancreatic cancer. Anticancer Agents
Med Chem. 11:418–426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar
|
|
35.
|
Rocha Lima CM, Green MR, Rotche R, Miller
WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G and
Miller LL: Irinotecan plus gemcitabine results in no survival
advantage compared with gemcitabine monotherapy in patients with
locally advanced or metastatic pancreatic cancer despite increased
tumor response rate. J Clin Oncol. 22:3776–3783. 2004.
|
|
36.
|
Louvet C, Labianca R, Hammel P, Lledo G,
Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J,
Faroux R, Lepere C and de Gramont A; GERCOR; GISCAD: Gemcitabine in
combination with oxaliplatin compared with gemcitabine alone in
locally advanced or metastatic pancreatic cancer: results of a
GERCOR and GISCAD phase III trial. J Clin Oncol. 23:3509–3516.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Oettle H, Richards D, Ramanathan RK, van
Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, von Hoff D,
Arning M and Kindler HL: A phase III trial of pemetrexed plus
gemcitabine versus gemcitabine in patients with unresectable or
metastatic pancreatic cancer. Ann Oncol. 16:1639–1645. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Abou-Alfa GK, Letourneau R, Harker G,
Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, de Jager
RL, Eckhardt SG and O’Reilly EM: Randomized phase III study of
exatecan and gemcitabine compared with gemcitabine alone in
untreated advanced pancreatic cancer. J Clin Oncol. 24:4441–4447.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kim YR, Byun HS, Jeon J, Choi BL, Park KA,
Won M, Zhang T, Shin S, Lee H, Oh J and Hur GM: Apoptosis
signal-regulating kinase1 is inducible by protein kinase C δ and
contributes to phorbol ester-mediated G1 phase arrest through
persistent JNK activation. Cell Biochem Biophys. 61:199–207.
2011.PubMed/NCBI
|
|
40.
|
Engedal N, Korkmaz CG and Saatcioglu F:
C-Jun N-terminal kinase is required for phorbol ester- and
thapsigargin-induced apoptosis in the androgen responsive prostate
cancer cell line LNCaP. Oncogene. 21:1017–1027. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Ikezoe T, Yang Y, Taguchi H and Koeffler
HP: JNK interacting protein 1 (JIP-1) protects LNCaP prostate
cancer cells from growth arrest and apoptosis mediated by
12-0-tetradecanoylphorbol-13-acetate (TPA). Br J Cancer.
90:2017–2024. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Tahara E, Kadara H, Lacroix L, Lotan D and
Lotan R: Activation of protein kinase C by phorbol 12-myristate
13-acetate suppresses the growth of lung cancer cells through KLF6
induction. Cancer Biol Ther. 8:801–807. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Huang P, Chubb S, Hertel LW, Grindey GB
and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA
synthesis. Cancer Res. 51:6110–6117. 1991.
|
|
44.
|
Ruiz van Haperen VW, Veerman G, Vermorken
JB and Peters GJ: 2′,2′-Difluoro-deoxycytidine (gemcitabine)
incorporation into RNA and DNA of tumour cell lines. Biochem
Pharmacol. 46:762–766. 1993.
|
|
45.
|
Tolis C, Peters GJ, Ferreira CG, Pinedo HM
and Giaccone G: Cell cycle disturbances and apoptosis induced by
topotecan and gemcitabine on human lung cancer cell lines. Eur J
Cancer. 35:796–807. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Pauwels B, Korst AE, Pattyn GG, Lambrechts
HA, van Bockstaele DR, Vermeulen K, Lenjou M, de Pooter CM,
Vermorken JB and Lardon F: Cell cycle effect of gemcitabine and its
role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol
Biol Phys. 57:1075–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Bouffard DY and Momparler RL: Comparison
of the induction of apoptosis in human leukemic cell lines by
difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. Leuk
Res. 19:849–856. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Ferreira CG, Tolis C, Span SW, Peters GJ,
van Lopik T, Kummer AJ, Pinedo HM and Giaccone G: Drug-induced
apoptosis in lung cancer cells is not mediated by the Fas/FasL
(CD95/APO1) signaling pathway. Clin Cancer Res. 6:203–212.
2000.PubMed/NCBI
|
|
49.
|
Teraishi F, Zhang L, Guo W, Dong F, Davis
JJ, Lin A and Fang B: Activation of c-Jun NH2-terminal kinase is
required for gemcitabine’s cytotoxic effect in human lung cancer
H1299 cells. FEBS Lett. 579:6681–6687. 2005.PubMed/NCBI
|
|
50.
|
Osada S, Tomita H, Tanaka Y, Tokuyama Y,
Tanaka H, Sakashita F and Takahashi T: The utility of vitamin K3
(menadione) against pancreatic cancer. Anticancer Res. 28:45–50.
2008.PubMed/NCBI
|
|
51.
|
Kreutzer JN, Ruzzene M and Guerra B:
Enhancing chemosensitivity to gemcitabine via RNA interference
targeting the catalytic subunits of protein kinase CK2 in human
pancreatic cancer cells. BMC Cancer. 10:4402010. View Article : Google Scholar
|
